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http://www.biomedcentral.com/1471-2377/14/212RESEARCH ARTICLE Open AccessImproved nutritional status is related to improved
quality of life in Parkinson’s disease
Jamie M Sheard1,2*, Susan Ash1, George D Mellick3, Peter A Silburn4 and Graham K Kerr1,2Abstract
Background: Quality of life is poorer in Parkinson’s disease than in other conditions and in the general population
without Parkinson’s disease. Malnutrition also results in poorer quality of life. This study aimed at determining the
relationship between quality of life and nutritional status.
Methods: Community-dwelling people with Parkinson’s disease >18 years old were recruited. The Patient-Generated
Subjective Global Assessment (PG-SGA) assessed nutritional status. The Parkinson’s Disease Questionnaire 39 (PDQ-39)
measured quality of life. Phase I was cross-sectional. The malnourished in Phase I were eligible for a nutrition
intervention phase, randomised into 2 groups: standard care (SC) with provision of nutrition education materials
only and intervention (INT) with individualised dietetic advice and regular weekly follow-up. Data were collected
at baseline, 6 weeks, and 12 weeks.
Results: Phase I consisted of 120 people who completed the PDQ-39. Phase II consisted of 9 in the SC group
and 10 in the INT group. In Phase I, quality of life was poorer in the malnourished, particularly for mobility and
activities of daily living domains. There was a significant correlation between PG-SGA and PDQ-39 scores (Phase I,
rs = 0.445, p = .000; Phase II, rs = .426, p = .002). In Phase II, no significant difference in the PDQ-39 total or sub-scores
was observed between the INT and SC groups; however, there was significant improvement in the emotional
well-being domain for the entire group, X2(2) = 8.84, p = .012.
Conclusions: Malnourished people with Parkinson’s disease had poorer quality of life than the well-nourished, and
improvements in nutritional status resulted in quality of life improvements. Attention to nutritional status is an
important component of quality of life and therefore the total care of people with Parkinson’s disease.
Trial registration: ACTRN12610000819022
Keywords: Malnutrition, Parkinson disease, Quality of life, Nutritional status, Nutrition therapyBackground
Quality of life is positively associated with quality of
health [1] and is therefore recognised as an important
outcome for the treatment of many conditions, including
Parkinson’s disease (PD). Reports about quality of life in
PD indicate that it is poor compared to that of the general
population [2,3] and in other conditions, [4,5] with vir-
tually all aspects of the disease contributing to poorer
quality of life. These include longer disease duration,* Correspondence: jamiesheard@gmail.com
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unless otherwise stated.[6] older age at disease onset, [7] more severe motor
symptoms, [4,6,8,9] decreases in mobility [10] and the
ability to carry out activities of daily living, [9,11,12]
increases in the amount of medication required, [4,12]
medication ineffectiveness, [4,13,14] dyskinesias, [13,15,16]
pain, [8,10] problems with sleep, [4,8,10] cognitive impair-
ment, [17] depression, [8-12,14] and anxiety [10,12,14].
Poor nutritional status, specifically malnutrition, results
in a lower quality of life in the elderly [18,19] and other
disease states [20-22]. People with PD are at risk of mal-
nutrition; [23-25] therefore, it is possible that malnutrition
in PD contributes to poorer quality of life, as a recent
study demonstrated, with significant correlations between
nutritional status and quality of life [26]. Factors affecting
a person’s food intake, such as difficulties swallowing andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[27]. Nutrition interventions aimed at improving these
symptoms and, therefore, nutritional status can improve
quality of life, as has previously been demonstrated in
chronic kidney disease [22] and oncology [21,28,29]
patients. Despite the extensive research related to quality
of life in PD, there is limited evidence regarding the rela-
tionship between malnutrition and quality of life. There is
also a paucity of information available about the results of
nutrition interventions for malnutrition in PD in general
and also as they affect quality of life.
The aim of the current study was to determine the rela-
tionship between nutritional status and quality of life in
people with PD.
Methods
The research was carried out in two phases. Informed
written consent for both phases was obtained as per
protocol approved by the Queensland University of
Technology Human Research Ethics Committee.
In Phase I, community-dwelling people with idiopathic
PD, aged >18 years, were recruited using a variety of
methods between February and August 2011 [25]. Par-
ticipants were excluded if they resided in an assisted
living facility. Geographical location was limited to
within ~2-hour driving distance of Brisbane, Queensland,
Australia. PD diagnosis was determined by the partici-
pants’ physician or neurologist and was self-reported
by the participant. Only a portion of the total data col-
lected, as it relates to nutritional status and quality of
life, is presented here, with other information regarding
clinical status, motor symptoms, and non-motor symp-
toms reported previously [25,30].
For the majority of the participants, the assessments
were conducted in their home, and the visit was sched-
uled to be within an hour of a PD medication dose or at
a time when the participants stated that their function
was best, to try to capture their function in an “On”
state. The scored Patient-Generated Subjective Global
Assessment (PG-SGA) was performed by a dietitian to
assess nutritional status [31]. Nutrition assessment using
the PG-SGA is based on a medical history (recent changes
in weight, dietary intake, gastrointestinal symptoms, func-
tional capacity, and disease status) and a physical examin-
ation of fat stores, muscle status, and fluid status. The
assessment results in a categorisation of nutrition status:
SGA-A (well nourished), SGA-B (moderately malnour-
ished), or SGA-C (severely malnourished) [32], as well
as a total score with a higher score indicating poorer
nutritional status. The PG-SGA score places people
into triage categories indicating the need for nutrition
or medical intervention: 0-1 points (category 1, no inter-
vention required), 2-3 points (category 2, patient and fam-
ily education required), 4-8 points (category 3, requiresintervention by dietitian), ≥9 (category 4, critical need for
symptom management and/or nutrition intervention).
The Parkinson’s Disease Questionnaire (PDQ-39) [33]
was completed to assess quality of life related to PD. A
higher score indicates poorer quality of life. It was
completed by the participants while the researcher was
present in order that instructions could be provided
that an answer of “Always” or “Cannot do at all” was
appropriate if they no longer performed a task due to
the difficulties associated with their PD. In the case of
poor cognitive status, as assessed by the Addenbrooke
Cognitive Examination, the spouse or caregiver was
asked to assist with completing the questionnaire. Each
of the PDQ-39 sub-scores was also calculated: mobility,
activities of daily living (ADL), emotional well-being
(EWB), stigma, social support, cognition, communica-
tion, and bodily discomfort. The Unified Parkinson’s
Disease Rating Scale (UPDRS) motor sub-scale (III)
was completed as previously described [30]. Birth date
and self-reported disease duration (PD duration) were
collected.
During Phase II, participants were considered eligible
when they were assessed as being at risk of malnutrition
or malnourished in Phase I using one of the following cri-
teria: SGA category B or C, Mini-Nutritional Assessment
(MNA) score ≤23.5, PG-SGA score ≥9, BMI <22 kg/m2
for participants aged ≥65 years, or BMI <18 kg/m2 for
participants aged ≤64 years. The inclusion criteria in-
cluded both those at risk of malnutrition and malnour-
ished in order to follow the recommendation that those
at risk of malnutrition should receive some intervention
[34] and to provide a sample size of 20 participants,
given the time limitations of the study. Exclusion criteria
included current management by a dietitian, hospitalisa-
tion at the time of intervention, deep brain stimulation
scheduled within the next 3 months, significant recent
improvement in nutritional status prior to Phase I,
intentional weight loss resulting in reduced intake and
low MNA score, and MNA score ≤23.5 or BMI < age-spe-
cific cut-offs but no significant changes in diet history, an-
thropometry, recent weight history, or functional status
and were deemed to be of normal nutritional status by the
dietitian [35].
The participants were randomised to 2 groups (SC:
standard care; INT: intervention) using a random num-
ber generator to assign participant numbers, and the
group assignments were placed in sealed envelopes,
with the number on the outside, by a research associate
not associated with the project. Rolling recruitment was
conducted to allow for Phase II to run concurrently with
the end of Phase I. As eligible participants agreed to
participate, they were assigned the next consecutive
number, which identified the envelope to open to de-
termine the group assignment.
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over a 12-week period. The SC group received written
information only while the INT group received indivi-
dualised nutrition information by a dietitian and weekly
phone contact. The participants were informed of the
groups, including that one would include more infor-
mation and contact than the other. Each participant
was involved in 4 visits: 1. Instruction visit (pre-BL)
one week prior to the baseline time point; 2. Baseline
measurements (BL); 3. 6-week measurements (6 wk); 4.
12-week measurements (12 wk). These visits were con-
ducted at the same time every visit, similar to the
Phase I timing for as close to an “On” state as possible,
and the assessments were performed in the same order
to minimise the effects of medication on the outcomes.
Written consent was obtained at the pre-BL visit. The
PDQ-39, SGA, and PG-SGA were completed at the BL,
6 wk, and 12 wk visits but not the pre-BL visit. The
Hoehn and Yahr (H&Y) scale, which is a five-point
scale (1-5) with a higher rating on the scale indicating
a greater amount of disability and impairment, was
recorded. The H&Y scores were dichotomized (less
severe PD, H&Y 0-3; severe PD, H&Y 4-5). Current
medications were collected at each of the 4 visits, and
the levodopa equivalent doses (LEDD) were calculated
per kg body weight (mg/kg). Changes in medication
were at the treating physician’s or neurologist’s discretion
and were not controlled in the study. All participants
who required further intervention received referrals to a
dietitian after completion of the project.
Statistical analysis
Variables of interest were not normally distributed for
the SGA-A group or for each of the PG-SGA triage
categories. Therefore, median (range) values are reported
when comparing by groups, and non-parametric Mann-
Whitney U tests were conducted to compare the scores
between PG-SGA categories. Non-parametric independ-
ent samples Kruskal Wallis tests were conducted to
compare the scores between the PG-SGA triage categor-
ies. In Phase II, the Friedman’s Two-Way ANOVA by
ranks was conducted to determine differences in PDQ-
39 score for each group (SC, INT) as well as the entire
sample over the intervention period. The comparison
with the entire sample was conducted owing to the
small sample size and the potential that participants im-
proved their nutritional status as a result of knowledge
of their nutritional status at baseline. Spearman’s corre-
lations were conducted between PG-SGA and PDQ-39
scores and between PG-SGA score and each PDQ-39
sub-score. Median change in PDQ-39 score between
BL and wk 12 was calculated for each group. These
changes were compared between groups (SC, INT) using
non-parametric Mann-Whitney U tests. A change of 2points in the total score was considered clinically
meaningful [36].
A maximum likelihood linear mixed model with random
intercepts was used to analyse the longitudinal data
with PDQ-39 as the outcome variable and PD duration,
gender, dichotomized H&Y grouping, log-transformed
PG-SGA scores, intervention group (SC, INT), time (BL,
6 wk, 12 wk), and group*time interaction as fixed effects.
Statistical analysis was completed using SPSS Version
19 (SPSS Inc., Chicago, IL, USA). Statistical significance
was set at p <0.05.
Results
Phase I
One hundred twenty five community dwelling adults
aged >18 years (74 M, 51 F) participated in Phase I.
Median age of the participants was 70 (35–92) years.
Self-reported median length of disease was 6 (0–31)
years. The median H&Y score was 2 with 92.8% of par-
ticipants in the less severe category and 7.2% in the
more severe category. Nineteen (15.2%) participants
were moderately malnourished (SGA-B), while none
were severely malnourished (SGA-C). Further details
about the sample are available elsewhere [25]. Briefly, the
median UPDRS III score was 15 (1–37) in the SGA-A
group and 20 (11–39) in the SGA-B group (U = 1376.5,
z = 2.63, p = 0.008).
PDQ-39 scores were missing for 5 participants because
those participants did not wish to complete the entire
data collection visit. Therefore, analysis was only com-
pleted for 120 participants (103 SGA A, 17 SGA B)
with a median age of 71 (35–92) years and median self-
reported length of disease of 6 (0–26) years. Median
PG-SGA score was 2 (0–15) for SGA-A and 8 (4–15)
for SGA-B participants (U = 1611.5, z = 5.60, p = 0.000).
SGA-B participants had higher median PDQ-39 total
and sub-scores than SGA-A participants. These differ-
ences were statistically significant between the groups
in the mobility (U = 1195.00, z = 2.41, p = 0.016) and
activities of daily living (U = 1128.5, z = 2.67, p = 0.008)
sub-scores (Table 1).
PDQ-39 score was significantly different between tri-
age categories (X2(3) = 22.03, p = 0.000) (Table 2) with
post-hoc tests indicating that the differences were between
triage categories 1 and 3 (z = -3.94, p = 0.000) and triage
categories 1 and 4 (z = -3.65, p = 0.002). Significant differ-
ences also existed in the mobility sub-score (X2(3) = 36.06,
p = 0.000). Post-hoc analysis revealed differences between
categories 1 and 3 (z = -4.17, p = 0.000), categories 1 and 4
(z = -5.50, p = 0.000), and categories 2 and 3 (z = -3.21,
p = 0.008). The ADL sub-score was also significantly
different (X2(3) = 22.13, p = 0.000). Post-hoc analysis indi-
cated that these differences existed between categories
1 and 3 (z = -3.89, p = 0.001) and categories 1 and 4
Table 1 Differences in PDQ-39 score and sub-scores between SGA categories
SGA-A SGA-B PG-SGA score
n = 103 n = 17 rs, p value
PDQ-39 total score 23 (3–66) 28 (10–50) 0.445, .000*
Mobility sub-score 28 (0–100)* 45 (2–85)* 0.520, .000*
Activities of Daily Living sub-score 21 (0–100)* 42 (8–79)* 0.412, .000*
Emotional Wellbeing sub-score 17 (0–92) 29 (0–58) 0.243, .008*
Stigma sub-score 12 (0–69) 12 (0–75) 0.150, .101
Social Support sub-score 0 (0–75) 8 (0–50) 0.317, .000*
Cognition sub-score 31 (0–69) 31 (6–56) 0.239, .009*
Communication sub-score 17 (0–75) 25 (8–58) 0.212, .020*
Bodily discomfort sub-score 25 (0–100) 33 (0–75) 0.186, .042*
Abbreviations: PDQ-39 Parkinson’s Disease Questionnaire-39, PG-SGA Patient-Generated Subjective Global Assessment, SGA Subjective Global Assessment.
Values are reported as median (range) and compared using Mann-Whitney U tests and correlations between total PG-SGA score with PDQ-39 score and
sub-scores measured by Spearman’s correlation in Phase I.
*Statistically significant differences between groups, p < .05.
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score was also significantly different between the cat-
egories (X2(3) = 10.25, p = 0.017). Post-hoc analysis
resulted in differences between categories 1 and 3 only
(z = -2.72, p = 0.040).Table 2 Differences in PDQ-39 score and sub-scores between
PG-SGA triage categories
Triage category 1 Triage ca
(n = 35) (n = 37)
PDQ-39 total score
17* 20
(3 - 52) (5 - 58)
Mobility
5* 28*
(0 - 68) (0 - 79)
Activities of daily living
17* 21
(0 - 50) (0 - 79)
Emotional wellbeing
8 17
(0 - 58) (0 - 54)
Stigma
12 12
(0 - 56) (0 - 62)
Social support
0* 0
(0 - 50) (0 - 50)
Cognition
25 31
(0 - 69) (0 - 69)
Communication
17 17
(0 - 67) (0 - 67)
Bodily discomfort
25 33
(0 - 75) (0 - 75)
Abbreviations: PDQ-39 Parkinson’s Disease Questionnaire-39, PG-SGA Patient Genera
Values reported as median (range) and compared using Kruskal Wallis tests.
Triage category 1: No intervention required; Triage category 2: patient education re
for intervention.
*Statistically significant difference, p < .05.All of the correlations between PG-SGA score and
PDQ-39 total and sub-scores were significant except for
the stigma sub-score (Table 1). The strongest correla-
tions were between PG-SGA score, total PDQ-39 score
(rs = 0.445, p = 0.000), mobility sub-score (rs = 0.520,PG-SGA triage categories
tegory 2 Triage category 3 Triage category 4
(n = 32) (n = 16)
30.5* 28*
(10 - 66) (16 - 64)
45* 43.5*
(2 - 100) (10 - 85)
31* 40*
(4 - 100) (12 - 83)
31 23
(0 - 92) (0 - 75)
12 19
(0 - 75) (0 - 69)
8* 10
(0 - 75) (0 - 75)
31 41
(0 - 62) (6 - 62)
25 25
(0 - 75) (0 - 67)
29 42
(0 - 75) (0 - 100)
ted Subjective Global Assessment.
quired; Triage category 3: intervention required; Triage category 4: critical need
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p = 0.000).
Phase II
Twenty participants were eligible and agreed to partici-
pate in Phase II (Figure 1). One participant was excluded
after data collection due to excessive oedema that resulted
in an inability to monitor dry weight and weight changes
(SC, n = 9; INT, n = 10). Data may have also been affected
by the following: in the 2 weeks prior to the wk 12 visit, 1
INT injured her knee leaving her unable to mobilize well,
1 INT underwent esophageal surgery, and 1 INT suffered
from a gastrointestinal illness.
Median age of the group was 69.0 (35–84) years with a
median self-reported length of disease of 7.0 (1.5–26.5)Assessed for elig
SGA B/C = 19 + MNA 23.5 = 13 +
MNA  23.5 = 16 PG-SGA 9 = 2
PG-SGA 9 = 9 BMI 22 or 18.5 = 3
BMI 22 or 18.5 = 13
Analysed (n=10)
♦ Excluded from analysis (n=0)
Missing data:
n = 1, wk6 PDQ-39, did not finish visit
Lost to follow-up (n= 0)
Discontinued intervention (n=0) 
Allocated to Intervention (n= 10) 
♦ Received allocated intervention (n= 10)
♦ Did not receive allocated intervention 
(n= 0)
Randomi
Figure 1 CONSORT flow diagram of participant progression through thyears. The UPDRS III score in the SC group at BL was
18 (14–31) and in the INT group was 16.5 (9–30), and
the change in the UPDRS III score in the SC group was
0 (-2–9) and 0.5 (-7–3) in the INT group; neither the BL
value or change was significantly different between the
groups. The LEDD (mg/kg) was 11.0 (0–23.3) mg/kg in
the BL group and 8.4 (1.6–14.3) mg/kg in the INT
group; this was also not significantly different. Over the
12-week period, the LEDD (mg/kg) decreased by 0.13
(-2.94–1.7) mg/kg in the SC group and increased by 0.50
(-0.3–6.39) mg/kg in the INT group, which represented
a significant difference in the change between the groups
(U = 70.00, z = 2.04, p = 0.43).
The groups were not significantly different at baseline for
PDQ-39 scores, including the sub-scores. As a total group,ibility (n=41)
PG-SGA 9 = 7 + BMI 22 or 18.5 = 2
  BMI 22 or 18.5 = 1
Excluded  (n= 21) 
♦ Not meeting inclusion criteria (n=17) 
♦ Declined to participate (n= 4)
♦ Other reasons (n= 0) 
Lost to follow-up (n=0)
Discontinued intervention (n=0) 
Allocated to Standard Care (n= 10) 
♦ Received allocated intervention (n= 10)
♦ Did not receive allocated intervention 
(n= 0)
Analysed  (n=9) 
♦ Excluded from analysis (n=1)
Reason: excessive oedema and inability 
to monitor weight and nutritional status 
Missing data: n = 1, wk6 due to
hospitalisation for a fall and broken hip; n 
= 1, wk12 PDQ-39, did not finish visit
zed (n= 20) 
e RCT of nutrition intervention in people with Parkinson’s disease.
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23.5 (5–69), which is a clinically, but not statistically,
significant improvement (U = 3.11, p = 0.211). The only
sub-score to improve significantly for the total group
was the EWB sub-score (X2(2) = 8.84, p = 0.012), with
this change occurring between BL and wk 12 (z = 2.43,
p = 0.045) (Table 3).
The median change in total PDQ-39 score over the
12 weeks was not significantly different between the
groups (U = 33.00, z = -.894, p = 0.356) nor was there a
statistically significant change in either group over the
intervention period (SC, U = .74, p = 0.690; INT, U = 4.38,
p = 0.112). The change of 4 points in the PDQ-39 score
in the INT group was clinically significant, while the
improvement of 1.5 points in the SC group was not
(Table 3).
When all PDQ-39 measurements for all participants
across the 12 weeks were treated as one data set, there
was a significant positive correlation between PG-SGA
score and PDQ-39 score (rs = .426, p = 0.002), indicating
that poorer nutritional status was associated with poorer
quality of life. In the linear mixed models analysis, neither
the intervention group nor the intervention time period
had a significant effect on PDQ-39 score (Table 4). Nor did
gender or duration of disease at baseline demonstrate a
significant effect on PDQ-39 scores. The log-transformed
PG-SGA score bordered on statistical significance with
poorer nutritional status (higher PG-SGA score) resulting
in lower quality of life (higher PDQ-39 score), p = 0.051.
Dichotomised H&Y score had a significant effect on PDQ-
39 score with less severe disease resulting in better quality
of life (lower PDQ-39 score), p = 0.014.
Discussion
The current paper aimed to explore the relationship
between nutritional status and quality of life and also
to investigate the effect of a nutrition intervention on
quality of life in PD. In the current study, those whoTable 3 Baseline PDQ-39 score and sub-scores for each group
INT (n = 10) INT median change ove
PDQ-39 total score 22.5 (9 - 61) -4 (-17 - 8)
Mobility 45 (5 - 78) -2.5 (-28 - 30)
Activities of daily living 25 (17 - 62) -5 (-33 - 33)
Emotional wellbeing* 8 (0 - 71) -4 (-25 - 4)
Stigma 12.5 (0 - 56) 0 (-19 - 18)
Social support 4 (0 - 75) -4 (-13 - 8)
Cognition 19 (0 - 38) 3 (-12 - 13)
Communication 29 (8 - 75) -4 (-25 - 9)
Bodily discomfort 37.5 (0 - 67) -4 (-25 - 9)
Abbreviations: PDQ-39 Parkinson’s disease questionnaire-39, INT Intervention group,
*The score for the entire group improved significantly over the 12 week period, p <were malnourished reported lower quality of life across
the majority of PDQ-39 domains, and there were signifi-
cant relationships between nutritional status (PG-SGA
scores) and PDQ-39 scores, indicating poorer quality of
life in those with poorer nutritional status and supporting
previous findings in a sample of PD patients attending a
movement disorders clinic in Iran [26].
The strongest relationships existed between nutritional
status and the areas of mobility and activities of daily
living, and these were the domains that differentiated
the well-nourished and malnourished. Similar results
were recently reported in the study based in Iran, with
the strongest correlation between the PDQ-39 mobility
sub-score and nutritional status [26]. Therefore, perceived
limitations in mobility may have the greatest relationship
with nutritional status in PD. However, the precedence of
these relationships cannot be determined owing to the
cross-sectional nature of the present study. Poor mobility
and the inability to carry out ADL can contribute to poor
nutritional status [37]. On the other hand, malnutrition
reduces mobility [38] and functional status, [18,39] and
the ability to carry out activities of daily living plays an im-
portant part in quality of life [27,40]. Similarly, the finding
of poorer social support in those with poorer nutritional
status may be due to the fact that people with PD who live
alone are more likely to be malnourished [30]. Social sup-
port plays an important role in maintaining nutritional
status, particularly in a disease that results in considerable
disability [37] and nutrition impact symptoms that can
decrease food intake [25]. Therefore, these relationships
should be explored further to determine the influence
of the variables on each other.
There was also a positive relationship between changes
in PG-SGA and PDQ-39 scores during the 12-week
intervention period, regardless of the group (SC or INT)
(Table 4). Although these results only bordered on
significance, potentially because of the small sample
size, the findings might indicate that improvementsand the median change in scores over the 12 weeks
r 12 wks SC (n = 9) SC median change over 12 wks
28 (11 - 51) -1.5 (-8 - 23)
43.5 (2 - 88) 1.5 (-25 - 36)
42 (21 - 71) 0 (-13 - 17)
29 (4 - 67) -6.5 (-17 - 33)
3 (0 - 62) 0 (-6 - 12)
0 (0 - 50) 0 (-17 - 67)
34.5 (19 - 50) 0 (-19 - 18)
17 (0 - 67) 0 (-17 - 16)
33 (0 - 92) 0 (-25 - 9)
SC Standard Care group.
.05.
Table 4 Predictors of quality of life (PDQ-39 score) over the 12-week intervention period
Estimate Standard error Estimated marginal means p value
Intercept 48.02 14.01 n/a .003
Gender (male) -0.70 7.27
37.94 (male)
.316
38.64 (female)
PD duration (years) -0.80 0.69 n/a .265
H&Y category (less severe) -30.42 10.88
23.08 (less severe)
.014
53.50 (severe)
ln PG-SGA 5.37 2.67 n/a .051
Group (SC) 7.51 7.27
40.38 (SC)
.316
36.20 (INT)
Time (BL) 4.33 2.38 39.47 (BL) .079
37.85 (wk 6)
Time (wk 6) 2.87 2.50 .261
37.56 (wk 12)
Abbreviations: BL baseline, H&Y Hoehn & Yahr, PD Parkinson’s disease, PDQ-39 Parkinson’s disease questionnaire-39, PG-SGA Patient-Generated Subjective Global
Assessment, SC Standard Care.
AIC = 340.43; Estimated Marginal Means evaluated at ln PG-SGA 1.46 and PD duration 8.11 years.
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of life in PD.
Quality of life scores improved in both groups over
the 12-week period, although these changes were not
statistically significant. However, the INT group demon-
strated a trend towards greater improvement than the
SC group in the majority of domains, which resulted in
clinically significant changes. The collaborative and
personalised advice and the regular phone contact with
a health professional in the INT group may have
improved the group’s overall sense of well-being. It has
been shown that patient involvement in medical treat-
ment decisions increases the satisfaction with that
treatment in people with PD, and this may also extend
to nutrition-related interventions [41]. Participation in
the study also resulted in significantly improved emo-
tional well-being for the entire group. Perhaps even
semi-regular contact with a health professional may
improve the sense of being looked after.
Several factors may have resulted in a smaller effect of
the intervention than may have otherwise been found. One
is the small sample size, which is likely to have been under-
powered to detect a difference. In Phase II particularly, this
limits the ability to generalize the findings. However, given
the limited evidence in this area, especially for nutrition in-
terventions, this information helps to highlight the import-
ance of nutritional status in the well-being of people with
PD. Owing to the small sample size, more robust analysis
could not be conducted to control for other confounding
factors for either nutritional status or quality of life, such as
motor function, depression, or other non-motor symptoms.
Therefore, other factors such as depression, which is com-
mon with poor nutritional status, could have affected
quality of life more than nutritional status per se.There was also a large degree of variability in the
responses as is demonstrated by the wide ranges within
each PDQ-39 score. Within the INT group, there were
three individuals who experienced changes in their health,
unrelated to PD, in the weeks prior to the final data collec-
tion, resulting in poorer quality of life scores for them at
that final time point. In addition, there were participants
in both groups with missing data, particularly for the
PDQ-39, because they did not want to finish the visit. This
may have affected the comparison between the groups at
those times. Furthermore, the quality of life in this sample
was better than that reported in other studies, [14,42]
which could limit the ability to affect a significant change
in quality of life. The short study period of only 12 weeks
may not have allowed for meaningful changes in quality of
life to occur.
The choice of tool with which to measure quality of
life may have also affected the results. It has been argued
that the PDQ-39 measures health status (HS) rather
than quality of life, where HS refers to function levels,
and quality of life reflects internal experiences or the
subjective evaluation of health [43]. The PDQ-39 is
weighted toward physical symptoms and therefore may
not appropriately measure health-related quality of life
[44]. This may explain why the only significant improve-
ment was found in the emotional well-being domain
over the intervention period. Additionally, other import-
ant health related areas may be missing from the PDQ-39,
such as those relating to motor fluctuations and medica-
tions [45] which may be influenced by body weight and
nutritional status [46-48]. Finally, the use of self-reported
PD diagnosis to identify participants may influence the
generalisability of the results to patients with idiopathic
PD, as not all patients are aware of their specific diagnosis
Sheard et al. BMC Neurology 2014, 14:212 Page 8 of 9
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Conclusions
Malnourished people with PD presented with poorer
quality of life than well-nourished participants. This was
particularly evident in the areas of mobility and activities
of daily living, both of which have been associated with
poor nutritional status in other groups. Given the bor-
derline significant relationship between improvements
in nutritional status during the nutrition intervention
and improvements in quality of life, it is likely that future
studies conducted in larger samples would support this
finding. Furthermore, the nutrition intervention resulted
in improvements in emotional well-being. Attention to
nutritional status is an important component of quality of
life and therefore the total care of people with PD.
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